Difference between revisions of "Ceftibuten"

(Created page with "==General== *Type: *Dosage Forms: *Common Trade Names: ==Adult Dosing== ==Pediatric Dosing== ==Special Populations== *Pregnancy Rating: *Lac...")
 
 
(8 intermediate revisions by 6 users not shown)
Line 1: Line 1:
 
==General==
 
==General==
*Type:  
+
*Type: Third generation [[cephalosporin]]
*Dosage Forms:
+
*Dosage Forms: capsule, oral suspension
*Common Trade Names:  
+
*Dosage Strengths: capsule: 400mg; oral suspension: 90mg/5mL, 180mg/5mL
 +
*Routes of Administration: PO
 +
*Common Trade Names: Cedax
  
 
==Adult Dosing==
 
==Adult Dosing==
 +
===Chronic [[bronchitis]], acute exacerbation===
 +
*400mg PO qd x10 days
 +
===[[Otitis media]], acute===
 +
*400mg PO qd x10 days
 +
===[[Pharyngitis]]/Tonsillitis, streptococcal===
 +
*400mg PO qd x10 days
  
 
==Pediatric Dosing==
 
==Pediatric Dosing==
 +
===[[Otitis media]], acute===
 +
*6 mo - 11 yo, <45kg
 +
**9 mg/kg PO qd x10 days
 +
**Max: 400 mg/day
 +
*12+ yo, >45kg
 +
**400mg PO qd x10 days
 +
===[[Pharyngitis]]/Tonsillitis, streptococcal===
 +
*6 mo - 11 yo, <45kg
 +
**9 mg/kg PO qd x10 days
 +
**Max: 400 mg/day
 +
*12+ yo, >45kg
 +
**400mg PO qd x10 days
 +
===[[Pneumonia]], Community-acquired===
 +
*6 mo - 11 yo, <45kg
 +
**9 mg/kg PO qd x10 days
 +
**Max: 400 mg/day
 +
*12+ yo, >45kg
 +
**400mg PO qd x10 days
  
 
==Special Populations==
 
==Special Populations==
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]:
+
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B
*Lactation:
+
*Lactation: Probably safe
 +
 
 
*Renal Dosing
 
*Renal Dosing
 
**Adult
 
**Adult
 +
***CrCl 30-49: 200mg qd
 +
***CrCl  5-29: 100mg qd
 +
***CrCl    <5: Not defined
 +
***HD: 400mg after each dialysis
 +
***PD: No supplement
 
**Pediatric
 
**Pediatric
 +
***CrCl 30-49: 4.5 mg/kg qd, max 200mg/day
 +
***CrCl  5-29: 2.25 mg/kg qd, max 100mg/day
 +
***CrCl    <5: Not defined
 +
***HD: 9mg/kg after each dialysis, max 400mg;day
 +
***PD: No supplement
 
*Hepatic Dosing
 
*Hepatic Dosing
 
**Adult
 
**Adult
 +
***Not defined
 
**Pediatric
 
**Pediatric
 +
***Not defined
  
 
==Contraindications==
 
==Contraindications==
*Allergy to class/drug
+
*Hypersensitivity to class/drug
 +
*Caution:
 +
**Hypersensitivity to PCN
 +
**Renal impairment
 +
**Concurrent nephrotoxic agent
 +
**Seizure disorder
 +
**Recent antibiotic-associated colitis
  
 
==Adverse Reactions==
 
==Adverse Reactions==
 
===Serious===
 
===Serious===
 
+
*Allergy to class/drug
 +
*Serum sickness-like reaction
 +
*[[Stevens-Johnson syndrome]]
 +
*Exfoliative dermatitis
 +
*[[Erythema multiforme]]
 +
*Toxic epidermal necrolysis
 +
*Interstitial nephritis
 +
*Superinfection
 +
*C. difficile associated [[diarrhea]]
 +
*[[Seizure]]
 +
*[[Pancytopenia]]
 
===Common===
 
===Common===
 +
*[[Nausea]]
 +
*[[Diarrhea]]
 +
*Elevated BUN
 +
*[[Headache]]
 +
*[[Eosinophilia]]
 +
*Dyspepsia
 +
*[[Vomiting]]
 +
*[[Abdominal pain]]
 +
*[[Anemia]]
  
 
==Pharmacology==
 
==Pharmacology==
*Half-life:  
+
*Half-life: 2-2.5 hr; 13.4 hr if CrCl 5-29
*Metabolism:  
+
*Metabolism: Other
*Excretion:  
+
*Excretion: Urine 56%, Feces 39%
*Mechanism of Action:
+
*Mechanism of Action: Bactericidal; inhibits cell wall mucopeptide synthesis
  
 
==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>==
 
==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>==
Line 154: Line 218:
 
{{Template:Antibacterial Spectra Key}}
 
{{Template:Antibacterial Spectra Key}}
 
==See Also==
 
==See Also==
 +
*[[Antibiotics (Main)]]
  
==Source==
+
==References==
 +
<references/>
  
<references/>
+
[[Category:Pharmacology]] [[Category:ID]]

Latest revision as of 22:02, 19 September 2019

General

  • Type: Third generation cephalosporin
  • Dosage Forms: capsule, oral suspension
  • Dosage Strengths: capsule: 400mg; oral suspension: 90mg/5mL, 180mg/5mL
  • Routes of Administration: PO
  • Common Trade Names: Cedax

Adult Dosing

Chronic bronchitis, acute exacerbation

  • 400mg PO qd x10 days

Otitis media, acute

  • 400mg PO qd x10 days

Pharyngitis/Tonsillitis, streptococcal

  • 400mg PO qd x10 days

Pediatric Dosing

Otitis media, acute

  • 6 mo - 11 yo, <45kg
    • 9 mg/kg PO qd x10 days
    • Max: 400 mg/day
  • 12+ yo, >45kg
    • 400mg PO qd x10 days

Pharyngitis/Tonsillitis, streptococcal

  • 6 mo - 11 yo, <45kg
    • 9 mg/kg PO qd x10 days
    • Max: 400 mg/day
  • 12+ yo, >45kg
    • 400mg PO qd x10 days

Pneumonia, Community-acquired

  • 6 mo - 11 yo, <45kg
    • 9 mg/kg PO qd x10 days
    • Max: 400 mg/day
  • 12+ yo, >45kg
    • 400mg PO qd x10 days

Special Populations

  • Renal Dosing
    • Adult
      • CrCl 30-49: 200mg qd
      • CrCl 5-29: 100mg qd
      • CrCl <5: Not defined
      • HD: 400mg after each dialysis
      • PD: No supplement
    • Pediatric
      • CrCl 30-49: 4.5 mg/kg qd, max 200mg/day
      • CrCl 5-29: 2.25 mg/kg qd, max 100mg/day
      • CrCl <5: Not defined
      • HD: 9mg/kg after each dialysis, max 400mg;day
      • PD: No supplement
  • Hepatic Dosing
    • Adult
      • Not defined
    • Pediatric
      • Not defined

Contraindications

  • Hypersensitivity to class/drug
  • Caution:
    • Hypersensitivity to PCN
    • Renal impairment
    • Concurrent nephrotoxic agent
    • Seizure disorder
    • Recent antibiotic-associated colitis

Adverse Reactions

Serious

Common

Pharmacology

  • Half-life: 2-2.5 hr; 13.4 hr if CrCl 5-29
  • Metabolism: Other
  • Excretion: Urine 56%, Feces 39%
  • Mechanism of Action: Bactericidal; inhibits cell wall mucopeptide synthesis

Antibiotic Sensitivities[1]

Group Organism Sensitivity
Gram Positive Strep. Group A, B, C, G S
Strep. Pneumoniae I
Viridans strep R
Strep. anginosus gp X1
Enterococcus faecalis R
Enterococcus faecium X1
MSSA R
MRSA R
CA-MRSA R
Staph. Epidermidis R
C. jeikeium R
L. monocytogenes R
Gram Negatives N. gonorrhoeae I
N. meningitidis I
Moraxella catarrhalis S
H. influenzae S
E. coli S
Klebsiella sp S
E. coli/Klebsiella ESBL+ R
E coli/Klebsiella KPC+ R
Enterobacter sp, AmpC neg I
Enterobacter sp, AmpC pos R
Serratia sp I
Serratia marcescens X1
Salmonella sp S
Shigella sp S
Proteus mirabilis S
Proteus vulgaris S
Providencia sp. S
Morganella sp. R
Citrobacter freundii R
Citrobacter diversus S
Citrobacter sp. S
Aeromonas sp S
Acinetobacter sp. R
Pseudomonas aeruginosa R
Burkholderia cepacia S
Stenotrophomonas maltophilia R
Yersinia enterocolitica S
Francisella tularensis X1
Brucella sp. X1
Legionella sp. R
Pasteurella multocida X1
Haemophilus ducreyi X1
Vibrio vulnificus X1
Misc Chlamydophila sp X1
Mycoplasm pneumoniae X1
Rickettsia sp X1
Mycobacterium avium X1
Anaerobes Actinomyces X1
Bacteroides fragilis R
Prevotella melaninogenica X1
Clostridium difficile X1
Clostridium (not difficile) X1
Fusobacterium necrophorum X1
Peptostreptococcus sp. X1

Key

  • S susceptible/sensitive (usually)
  • I intermediate (variably susceptible/resistant)
  • R resistant (or not effective clinically)
  • S+ synergistic with cell wall antibiotics
  • U sensitive for UTI only (non systemic infection)
  • X1 no data
  • X2 active in vitro, but not used clinically
  • X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
  • X4 active in vitro, but not clinically effective for strep pneumonia

See Also

References

  1. Sanford Guide to Antimicrobial Therapy 2014